Cystic Fibrosis Improves COVID-19 Survival and Provides Clues for Treatment of SARS-CoV-2

Overview

Journal Purinergic Signal

Publisher Springer

Date 2021 May 10

PMID 33970408

Citations 13

Authors

Edward H Abraham

Guido Guidotti

Eliezer Rapaport

David Bower

Jack Brown

Robert J Griffin

Andrew Donnelly

Ellen D Waitzkin

Kenon Qamar

Mark A Thompson

Sukumar Ethirajan

Kent Robinson

Affiliations

Soon will be listed here.

Abstract

Systemic pools of ATP are elevated in individuals homozygous for cystic fibrosis (CF) as evidenced by elevated blood and plasma ATP levels. This elevated ATP level seems to provide benefit in the presence of advanced solid tumors (Abraham et al., Nature Medicine 2(5):593-596, 1996). We published in this journal a paper showing that IV ATP can elevate the depleted ATP pools of advanced cancer patients up to levels found in CF patients with subsequent clinical, biochemical, and quality of life (QOL) improvements (Rapaport et al., Purinergic Signalling 11(2): 251-262, 2015). We hypothesize that the elevated ATP levels seen in CF patients may be benefiting CF patients in another way: by improving their survival after contracting COVID-19. We discuss here the reasoning behind this hypothesis and suggest how these findings might be applied clinically in the general population.

Citing Articles

CFTR Inhibitors Display Antiviral Activity against Herpes Simplex Virus.

Jiang P, Dai Z, Yang C, Ding L, Li S, Xu X Viruses. 2024; 16(8).

PMID: 39205282 PMC: 11360776. DOI: 10.3390/v16081308.

Clinical Outcomes Following SARS-CoV-2 Infection in Pediatric Cystic Fibrosis Patients.

Huang A, Espina Rey A, Cherian C, Livingston F Cureus. 2024; 16(6):e62821.

PMID: 39036102 PMC: 11260353. DOI: 10.7759/cureus.62821.

Mechanisms by which the cystic fibrosis transmembrane conductance regulator may influence SARS-CoV-2 infection and COVID-19 disease severity.

Tedbury P, Manfredi C, Degenhardt F, Conway J, Horwath M, McCracken C FASEB J. 2023; 37(11):e23220.

PMID: 37801035 PMC: 10760435. DOI: 10.1096/fj.202300077R.

Gain- and Loss-of-Function Alleles Are Associated with COVID-19 Clinical Outcomes.

Baldassarri M, Zguro K, Tomati V, Pastorino C, Fava F, Croci S Cells. 2022; 11(24).

PMID: 36552859 PMC: 9776607. DOI: 10.3390/cells11244096.

The Potential of Purinergic Signaling to Thwart Viruses Including SARS-CoV-2.

Ferrari D, Rubini M, Burns J Front Immunol. 2022; 13:904419.

PMID: 35784277 PMC: 9248768. DOI: 10.3389/fimmu.2022.904419.

References

Abouelkhair M . Targeting adenosinergic pathway and adenosine A receptor signaling for the treatment of COVID-19: A hypothesis. Med Hypotheses. 2020; 144:110012. PMC: 7303042. DOI: 10.1016/j.mehy.2020.110012. View

Valdivieso A, Santa-Coloma T . CFTR activity and mitochondrial function. Redox Biol. 2013; 1:190-202. PMC: 3757715. DOI: 10.1016/j.redox.2012.11.007. View

Abraham E, Vos P, Kahn J, Grubman S, Jefferson D, Ding I . Cystic fibrosis hetero- and homozygosity is associated with inhibition of breast cancer growth. Nat Med. 1996; 2(5):593-6. DOI: 10.1038/nm0596-593. View

Bezzerri V, Piacenza F, Caporelli N, Malavolta M, Provinciali M, Cipolli M . Is cellular senescence involved in cystic fibrosis?. Respir Res. 2019; 20(1):32. PMC: 6376730. DOI: 10.1186/s12931-019-0993-2. View

Laird E, Rhodes J, Kenny R . Vitamin D and Inflammation: Potential Implications for Severity of Covid-19. Ir Med J. 2020; 113(5):81. View

McFadyen J, Stevens H, Peter K . The Emerging Threat of (Micro)Thrombosis in COVID-19 and Its Therapeutic Implications. Circ Res. 2020; 127(4):571-587. PMC: 7386875. DOI: 10.1161/CIRCRESAHA.120.317447. View

Purpura M, Rathmacher J, Sharp M, Lowery R, Shields K, Partl J . Oral Adenosine-5'-triphosphate (ATP) Administration Increases Postexercise ATP Levels, Muscle Excitability, and Athletic Performance Following a Repeated Sprint Bout. J Am Coll Nutr. 2017; 36(3):177-183. DOI: 10.1080/07315724.2016.1246989. View

Stanton B, Hampton T, Ashare A . SARS-CoV-2 (COVID-19) and cystic fibrosis. Am J Physiol Lung Cell Mol Physiol. 2020; 319(3):L408-L415. PMC: 7518058. DOI: 10.1152/ajplung.00225.2020. View

Bosch L, Bosch B, De Boeck K, Nawrot T, Meyts I, Vanneste D . Cystic fibrosis carriership and tuberculosis: hints toward an evolutionary selective advantage based on data from the Brazilian territory. BMC Infect Dis. 2017; 17(1):340. PMC: 5429554. DOI: 10.1186/s12879-017-2448-z. View

10.

Choi H, Curhan G . Independent impact of gout on mortality and risk for coronary heart disease. Circulation. 2007; 116(8):894-900. DOI: 10.1161/CIRCULATIONAHA.107.703389. View

11.

Gustafson C, Kim C, Weyand C, Goronzy J . Influence of immune aging on vaccine responses. J Allergy Clin Immunol. 2020; 145(5):1309-1321. PMC: 7198995. DOI: 10.1016/j.jaci.2020.03.017. View

12.

Woodward O, Tukaye D, Cui J, Greenwell P, Constantoulakis L, Parker B . Gout-causing Q141K mutation in ABCG2 leads to instability of the nucleotide-binding domain and can be corrected with small molecules. Proc Natl Acad Sci U S A. 2013; 110(13):5223-8. PMC: 3612674. DOI: 10.1073/pnas.1214530110. View

13.

Peckham D, McDermott M, Savic S, Mehta A . COVID-19 meets Cystic Fibrosis: for better or worse?. Genes Immun. 2020; 21(4):260-262. DOI: 10.1038/s41435-020-0103-y. View

14.

Callaway E . The coronavirus is mutating - does it matter?. Nature. 2020; 585(7824):174-177. DOI: 10.1038/d41586-020-02544-6. View

15.

Taghizadeh-Hesary F, Akbari H . The powerful immune system against powerful COVID-19: A hypothesis. Med Hypotheses. 2020; 140:109762. PMC: 7175888. DOI: 10.1016/j.mehy.2020.109762. View

16.

Lohman A, Billaud M, Isakson B . Mechanisms of ATP release and signalling in the blood vessel wall. Cardiovasc Res. 2012; 95(3):269-80. PMC: 3400358. DOI: 10.1093/cvr/cvs187. View

17.

Kuzuya M, Ando F, Iguchi A, Shimokata H . Effect of aging on serum uric acid levels: longitudinal changes in a large Japanese population group. J Gerontol A Biol Sci Med Sci. 2002; 57(10):M660-4. DOI: 10.1093/gerona/57.10.m660. View

18.

Withrock I, Anderson S, Jefferson M, McCormack G, Mlynarczyk G, Nakama A . Genetic diseases conferring resistance to infectious diseases. Genes Dis. 2018; 2(3):247-254. PMC: 6150079. DOI: 10.1016/j.gendis.2015.02.008. View

19.

Rapaport E, Salikhova A, Abraham E . Continuous intravenous infusion of ATP in humans yields large expansions of erythrocyte ATP pools but extracellular ATP pools are elevated only at the start followed by rapid declines. Purinergic Signal. 2015; 11(2):251-62. PMC: 4425716. DOI: 10.1007/s11302-015-9450-y. View

20.

Jordan A, Jurca R, Abraham E, Salikhova A, Mann J, Morss G . Effects of oral ATP supplementation on anaerobic power and muscular strength. Med Sci Sports Exerc. 2004; 36(6):983-90. DOI: 10.1249/01.mss.0000128198.97260.8b. View